The 120-pages report segments the global gastrointestinal diseases therapeutics market by drug class (anti-inflammatory and immunosuppressors, acid neutralizers, and other therapeutics) and geography (North America, Europe, Asia, and ROW).
By drug class, the anti-inflammatory and immunosuppressors segment generated maximum revenue in the market in 2021. The increasing prevalence of ulcerative colitis and Crohn's disease, the rising focus of vendors on developing biologics, and effective treatment results among the patients with IBDs are the factors contributing to the growth of the anti-inflammatory and immunosuppressors segment. The market growth in the segment will be significant during the forecast period.
Similarly, Asia will have the largest share of the market. The region currently holds 42% of the global market share. Rising healthcare expenditure is one of the major factors driving the growth of the regional market. China and Japan are the key markets for gastrointestinal diseases therapeutics in Asia. Market growth in this region will be faster than the growth of the market in other regions.
Identify other key segments, regions, and countries in the global gastrointestinal diseases therapeutics market. Request a Free Sample Report
The market is driven by the increasing incidence of gastrointestinal diseases. In addition, the strong product pipeline is anticipated to boost the growth of the gastrointestinal diseases therapeutics market.
Globally, the prevalence of various gastrointestinal diseases such as gallstones, ulcerative colitis, fissure, hemorrhoids, irritable bowel disease (IBD), and others have increased significantly over the years. These diseases if untreated in time could lead to various medical complications and disabilities. Hence, the demand for various medications, including antacids, histamine H2-receptor antagonists, laxatives, proton pump inhibitors, and antibiotics to cure such diseases has been on the rise. This is increasing the demand for various classes or types of drugs for treating gastrointestinal diseases, which, in turn, is boosting the growth of the global gastrointestinal diseases therapeutics market.
Major Companies in the Gastrointestinal Diseases Therapeutics Market:
The global gastrointestinal diseases therapeutics market is fragmented due to the presence of several global and local vendors. Established vendors are focusing on remaining competitive by investing in R&D activities to develop innovative therapeutics and strengthening their customer base with a strong network of distribution channels. However, the established vendors face a heavy threat from the generic drug manufacturers, owing to the increasing patent expiries in the market.
Technavio identifies the following as the key vendors in the market.
Abbott Laboratories: The company offers gastrointestinal disease therapeutics under various brands such as Actnew, Adiza, Cremadiet, Cremaffin, Cremagel, Cremalax, Eldicet, and others.
AbbVie Inc.: The company offers gastrointestinal diseases therapeutics products under the brands ACTIGALL, ASACOL HD, BENTYL, CANASA, CARAFATE, DELZICOL, and others.
AstraZeneca Plc: The company offers gastrointestinal diseases therapeutics products under the brands Losec, Gastroloc, Mopral, Omepral, Prilosec, Nexium, and Vimovo.
Bausch Health Companies Inc.: The company offers gastrointestinal diseases therapeutics under the brand Salix.
Boehringer Ingelheim International GmbH: The company offers gastrointestinal diseases therapeutics under the brands Dulcolax, Buscopan, Zantac, and Vaprino.
Technavio's sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.
Request a free sample report
Related Reports:
Gastrointestinal Bleeding Treatment Market by Product and Geography - Forecast and Analysis 2022-2026
Gastrointestinal Stents Market by Product, End-user, and Geography - Forecast and Analysis 2022-2026
Gastrointestinal Diseases Therapeutics Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2019 |
Forecast period |
2020-2024 |
Growth momentum & CAGR |
Accelerate at a CAGR of 9% |
Market growth 2020-2024 |
USD 22.82 billion |
Market structure |
Fragmented |
YoY growth (%) |
-28.49 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
Asia at 42% |
Key consumer countries |
US, Japan, China, Germany, and France |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Contents:
Executive Summary
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Drug class
- Market segments
- Comparison by Drug class
- Anti-inflammatory and immunosuppressors - Market size and forecast 2019-2024
- Acid neutralizers - Market size and forecast 2019-2024
- Other therapeutics - Market size and forecast 2019-2024
- Market opportunity by Drug class
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2019-2024
- Europe - Market size and forecast 2019-2024
- Asia - Market size and forecast 2019-2024
- ROW - Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
- Volume driver – Demand led growth
- Market challenges
- Market trends
Vendor Landscape
- Overview
- Vendor landscape
- Landscape disruption
- Industry risks
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Abbott Laboratories
- AbbVie Inc.
- AstraZeneca Plc
- Bausch Health Companies Inc.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Takeda Pharmaceutical Co. Ltd.
- UCB SA
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article